The role of asunercept as a selective CD95L inhibitor in cutaneous melanoma: Rationale and results from an enhanced TiRP model
Main Authors: | Krendyukov, A, Kneisel, N, Zhu, J, Merz, C, Richards, D, Gieffers, C, Van Den Eynde, B |
---|---|
Other Authors: | Mitchell, T |
Format: | Conference item |
Language: | English |
Published: |
Elsevier
2020
|
Similar Items
-
Asunercept as an innovative therapeutic approach for recurrent glioblastoma and other malignancies
by: Krendyukov A, et al.
Published: (2019-09-01) -
CD95L and Anti-Tumor Immune Response: Current Understanding and New Evidence
by: Richards DM, et al.
Published: (2021-03-01) -
Translational PBPK Modeling of the Protein Therapeutic and CD95L Inhibitor Asunercept to Develop Dose Recommendations for Its First Use in Pediatric Glioblastoma Patients
by: Nina Hanke, et al.
Published: (2019-04-01) -
Efficacy and safety of asunercept, a CD95L-selective inhibitor, in hospitalised patients with moderate-to-severe COVID-19: ASUNCTIS, a multicentre, randomised, open-label, controlled, phase 2 trialResearch in context
by: Maria Pilar Ruiz Seco, et al.
Published: (2024-11-01) -
The potential for BRAF V600 inhibitors in advanced cutaneous melanoma: rationale and latest evidence
by: Charlotte Lemech, et al.
Published: (2012-03-01)